Source - GNW
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
   
1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii
Summit Therapeutics PLC
Sedol BN40HZ0
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights  
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached  
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments  
An event changing the breakdown of voting rights X
Other (please specify):    
3. Full name of person(s) subject to the
notification obligation:
iii
1Lansdowne Partners International Limited

2Lansdowne Partners Limited

3Lansdowne Partners (UK) LLP
4. Full name of shareholder(s)
 (if different from 3.):iv
HSBC Client Holdings Nominee (UK) Ltd,
HSBC Bank Plc Lansdowne Markets

 

(Registered Shareholders)
5. Date of the transaction and date on
which the threshold is crossed or
reached:
v
13/10/2016
6. Date on which issuer notified: 18/10/2016
7. Threshold(s) that is/are crossed or
reached:
vi, vii
18% (Voting rights attached to shares only)


8. Notified details:
A: Voting rights attached to sharesviii, ix
Class/type of
shares


if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of  voting rights x
DirectDirect xiIndirect xiiDirectIndirect
Ordinary Shares 11,077,170 11,077,170     11,077,170   17.95%
GB00BN40HZ01
 
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Expiration
date
xiii
Exercise/
Conversion Period
xiv
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
rights
American Depositary Shares (ADS) N/A N/A 4,650,000 7.53%
 
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise priceExpiration date xviiExercise/
Conversion period
xviii
Number of voting rights instrument refers to

 
% of voting rights xix, xx

 
         

 
NominalDelta
   
 
Total (A+B+C)
Number of voting rightsPercentage of voting rights
15,727,170 25.48%


9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi
Lansdowne Partners International Limited is the parent undertaking of Lansdowne Partners Limited which is the First Corporate Member of Lansdowne Partners (UK) LLP
 
Proxy Voting:
10. Name of the proxy holder:  
11. Number of voting rights proxy holder will cease
to hold:
 
12. Date on which proxy holder will cease to hold
voting rights:
 
 

13. Additional information:
 

Based on total voting rights of 61,723,256

 

 
14. Contact name: Ruari Paton
15. Contact telephone number: +44 020 7290 5500



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Summit Therapeutics plc via Globenewswire

Related Charts

Summit Therapeutics (SUMM)

0.00 (0.00%)
delayed 18:15PM